Helex funding, investors and company details

Helex is an emerging Artificial Intelligence (AI) startup from Hyderabad, working in the space of early preclinical biotechnology company. Founded by Poulami Chaudhuri, Anirudh Nishtala, Rohini Kalvakuntla.

Company: Helex Biotech Limited
Sector: Artificial Intelligence (AI)
Location: Hyderabad
Founders: Poulami Chaudhuri, Anirudh Nishtala, Rohini Kalvakuntla
Total funding raised: ₹33.87 Cr

Company overview

Helex is an early preclinical biotechnology company based in the US and India, focused on developing genomic medicines for high-burden kidney diseases. They use proprietary lipid nanoparticle delivery systems combined with AI-driven genome editing technologies to create precise, scalable therapeutics. Their lead program targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), aiming to provide a one-time, mutation-agnostic gene-editing therapy. Founded in 2021 and incubated at the University of Hyderabad, Helex strives to transform treatment for chronic and rare kidney disorders through innovative, non-viral, programmable therapeutics. They have received significant recognition and funding in the biotech space.

Funding rounds

Latest round (seed): $ 3.50 Mn (₹33.87 Cr.). Investors: Pi Ventures, Bluehill.VC, SOSV